Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01657266
Recruitment Status : Unknown
Verified May 2014 by Laboratorios Sophia S.A de C.V..
Recruitment status was:  Recruiting
First Posted : August 6, 2012
Last Update Posted : May 20, 2014
Information provided by (Responsible Party):
Laboratorios Sophia S.A de C.V.

Brief Summary:
The purpose of this study is to evaluate efficacy and safety of the ophthalmic solution PRO-155 in patients post phacoemulsification.

Condition or disease Intervention/treatment Phase
Cataract Drug: PRO-155 Drug: Nevanac Phase 2

Detailed Description:

Postsurgical inflammation is an inevitable condition after cataract surgery. The use of non-steroidal anti-inflammatory drugs is a safe option for treating ocular inflammation.

This is a phase II randomized double-blind clinical trial. The aim is to compare and to evaluate efficacy and safety of two ophthalmic solutions in patients post phacoemulsification. Patients will be randomized to receive either PRO-155 or Nevanac for 60 days.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients
Study Start Date : December 2013
Estimated Primary Completion Date : May 2014
Estimated Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Nepafenac

Arm Intervention/treatment
Experimental: PRO-155
PRO-155 ophthalmic solution
Drug: PRO-155
instill one drop 2 times a day (BID) for 30 days

Active Comparator: Nevanac
Nepafenac Ophthalmic Solution 0.1%
Drug: Nevanac
instill one drop 2 times a day (BID) for 30 days
Other Name: Nepafenac

Primary Outcome Measures :
  1. cellularity in anterior chamber [ Time Frame: day 60 ]
    Change from Baseline in cellularity in anterior chamber after 60 days of treatment

  2. flare in anterior chamber [ Time Frame: day 60 ]
    Change from Baseline in flare in anterior chamber after 60 days of treatment

Secondary Outcome Measures :
  1. Ocular pain [ Time Frame: day 60 ]
    Number of patients without pain, would be measured using the Visual Analog Pain Scale

Other Outcome Measures:
  1. fluorescein dye [ Time Frame: day 60 ]
    Number of patients with normal fluorescein dye

  2. green lissamine dye [ Time Frame: day 60 ]
    Number of patients with normal green lissamine dye

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients older than 18 years who require cataract surgery
  • Both genders
  • Provide informed consent
  • Normal Laboratory results

Exclusion Criteria:

  • Patients with visual acuity of 20/40 or less in the contralateral eye of the surgery
  • Patients with any trans-surgical complication
  • Patients with a cataract >NC4, C4 or P4 classified with the system LOCS
  • Patients with any active corneal pathology
  • Patients under any steroidal treatment (topic, systemic or inhaled)14 days prior surgery or NSAIDs 7 days before the surgery (except low-dose aspirin)
  • Patients with IOP <5 or >21 mmHg
  • Patients that have ocular pain, cellularity or flare at the moment of selection
  • Patients with ocular exfoliation, trauma or any inflammatory disease
  • Patients with diabetic retinopathy that need treatment or uncontrolled diabetes mellitus
  • Patients who are planning cataract surgery of the contralateral eye 14 days after surgery of the study eye
  • Patients with history of hypersensitivity or contraindication for any drug used in the study
  • Patients under anticoagulant treatment
  • Contact lens users
  • Pregnant patients, at risk of pregnancy or breastfeeding
  • Patients without birth control treatment
  • Patients with any active toxicomanies (alcoholism, cigarette, cannabis or others)
  • Patients who had participated in any clinical trial in the last 90 days
  • Legal or mentally disabled patients who could not give informed consent
  • Patients who cannot comply with all study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01657266

Contact: Leopoldo M Baiza-Durán, MD +52(33) 30014200 ext 1051
Contact: Clotilde Ayala-Barajas, MSc +52(33) 30014200 ext 1074

Hospital Civil de Guadalajara Fray Antonio Alcalde Recruiting
Guadalajara, Jalisco, Mexico, 44280
Contact: Raul Bustos, MD    36145501 ext 121   
Sponsors and Collaborators
Laboratorios Sophia S.A de C.V.

Responsible Party: Laboratorios Sophia S.A de C.V. Identifier: NCT01657266     History of Changes
Other Study ID Numbers: SOPH155-0412/II
First Posted: August 6, 2012    Key Record Dates
Last Update Posted: May 20, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Lens Diseases
Eye Diseases
Ophthalmic Solutions
Pharmaceutical Solutions
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents